Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) FCF Margin (2020 - 2026)

ADC Therapeutics has reported FCF Margin over the past 7 years, most recently at 148.47% for Q1 2026.

  • Quarterly results put FCF Margin at 148.47% for Q1 2026, up 98349.0% from a year ago — trailing twelve months through Mar 2026 was 192.18% (up 4306.0% YoY), and the annual figure for FY2018 was 10645.79%, changed.
  • FCF Margin reached 148.47% in Q1 2026 per ADCT's latest filing, up from 186.45% in the prior quarter.
  • Across five years, FCF Margin topped out at 0.0% in Q3 2022 and bottomed at 1131.96% in Q1 2025.
  • Median FCF Margin over the past 5 years was 142.28% (2024), compared with a mean of 193.33%.
  • The largest annual shift saw FCF Margin plummeted -88477bps in 2025 before it skyrocketed 98349bps in 2026.
  • Over 5 years, FCF Margin stood at 0.2% in 2022, then crashed by -136798bps to 271.11% in 2023, then skyrocketed by 50bps to 136.1% in 2024, then tumbled by -37bps to 186.45% in 2025, then rose by 20bps to 148.47% in 2026.
  • Business Quant data shows FCF Margin for ADCT at 148.47% in Q1 2026, 186.45% in Q3 2025, and 127.86% in Q2 2025.